Genentech gets U.K. TPA approval

On the same day as the British court ruling, licensee Boehringer Ingelheim received U.K. approval to market TPA. Marketed outside the U.S. as Actilyse, the recombinant TPA will be launched in the U.K. by Boehringer during November. U.K. National Health Service has set the cost of the drug at (BRITISH POUND)960, or about $ 1,708 in U.S. dollars, per 100 mg dose. The U.K. price for TPA is similar to the drug's cost in another major European market for TPA, West Germany. TPA is going for 3,200 marks or $ 1,807 in U.S. dollars per 100 mg dose.